Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)
China · Delayed Price · Currency is CNY 19.05
+0.07 (0.37%)
Sep 14, 2026, 3:04 PM CST
SHE:300357 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 9,938 | 14,844 | 10,639 | 15,184 | 28,849 | 30,001 | |
Market Cap Growth | -39.32% | 39.52% | -29.93% | -47.37% | -3.84% | -25.29% |
Enterprise Value | 8,589 | 13,617 | 9,547 | 14,160 | 27,839 | 29,137 |
Last Close Price | 18.98 | 28.07 | 19.90 | 28.14 | 53.15 | 55.02 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 23.81 | 38.97 | 33.48 | 48.95 | 82.72 | 88.76 |
Forward PE | 21.94 | 33.35 | 26.80 | 38.41 | 62.09 | 69.52 |
PS Ratio | 9.10 | 13.97 | 11.50 | 17.90 | 32.20 | 37.15 |
PB Ratio | 3.50 | 5.47 | 4.33 | 6.59 | 14.23 | 16.70 |
P/TBV Ratio | 3.78 | 6.01 | 4.86 | 7.50 | 15.68 | 18.27 |
P/FCF Ratio | 30.98 | 54.79 | 79.92 | 98.21 | 180.74 | 126.95 |
P/OCF Ratio | 24.11 | 35.08 | 40.54 | 39.74 | 80.08 | 83.20 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.86 | 12.82 | 10.32 | 16.70 | 31.07 | 36.07 |
EV/EBITDA Ratio | 17.84 | 29.92 | 26.45 | 41.85 | 69.18 | 79.58 |
EV/EBIT Ratio | 20.34 | 33.59 | 30.08 | 46.13 | 72.86 | 84.20 |
EV/FCF Ratio | 26.78 | 50.26 | 71.72 | 91.59 | 174.41 | 123.29 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | 0.00 |
Debt / EBITDA Ratio | 0.04 | 0.04 | 0.07 | 0.18 | 0.04 | 0.02 |
Debt / FCF Ratio | 0.06 | 0.07 | 0.19 | 0.40 | 0.10 | 0.03 |
Net Debt / Equity Ratio | -0.50 | -0.52 | -0.52 | -0.53 | -0.55 | -0.56 |
Net Debt / EBITDA Ratio | -3.01 | -3.11 | -3.57 | -3.62 | -2.78 | -2.77 |
Net Debt / FCF Ratio | -4.47 | -5.22 | -9.68 | -7.93 | -7.01 | -4.29 |
Asset Turnover | 0.37 | 0.38 | 0.35 | 0.36 | 0.43 | 0.46 |
Inventory Turnover | 0.94 | 0.90 | 0.77 | 0.75 | 0.83 | 0.68 |
Quick Ratio | 8.82 | 11.59 | 8.58 | 8.43 | 13.72 | 11.76 |
Current Ratio | 9.14 | 12.18 | 9.05 | 8.87 | 14.38 | 12.42 |
Return on Equity (ROE) | 15.03% | 14.24% | 12.78% | 13.65% | 17.56% | 19.63% |
Return on Assets (ROA) | 8.99% | 9.04% | 7.53% | 8.06% | 11.56% | 12.23% |
Return on Invested Capital (ROIC) | 24.74% | 27.95% | 23.55% | 26.42% | 38.04% | 40.44% |
Return on Capital Employed (ROCE) | 14.70% | 14.70% | 12.60% | 12.90% | 18.20% | 19.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.20% | 2.57% | 2.99% | 2.04% | 1.21% | 1.13% |
FCF Yield | 3.23% | 1.82% | 1.25% | 1.02% | 0.55% | 0.79% |
Dividend Yield | 1.10% | 0.89% | 1.10% | 0.66% | 0.38% | 0.36% |
Payout Ratio | 27.62% | 30.27% | 30.66% | 34.05% | 30.17% | 24.79% |
Buyback Yield / Dilution | -0.00% | 0.01% | 0.00% | 0.00% | 0.00% | -0.00% |
Total Shareholder Return | 1.09% | 0.90% | 1.11% | 0.66% | 0.38% | 0.36% |